Gaining an Edge in the Cannabis Industry

This is a copy of the September 1st edition of our weekly Newsletter, which we have been publishing since October 2015.


This week, New Cannabis Ventures celebrated a milestone as we published our 100th industry leadership interview. We began this process just 19 months ago, a little more than 2 years after we launched the platform as another tool to help our audience discover under-the-radar private and public cannabis companies, gain a better understanding of some better known companies and to learn about some of their leading peers or peers of companies in which they invest. View our entire library of interviews.

The overriding goal of New Cannabis Ventures remains to provide a valued service to our readers by filtering a substantial amount of industry news, sharing only what we think our readers will find important and doing so in a timely manner. We supplement this with data-driven resources, such as the popularized public company revenue tracker, industry events, earnings call calendars, IPO and new issues tracker and six professionally managed family of stock indexes, as well as exclusive and original content. Simply put, all our published content is designed to give our readers an edge as they look to invest or operate in the cannabis industry. For investors who want an even bigger edge, we offer a premium service as well.

From a high level perspective, our interviews have been quite diverse, with 49% of the companies privately-held and over 30% from companies operating outside of the U.S. Though our industry struggles with diversity issues, 24% of the interviews we have conducted have been with females and minorities. We are pleased to conduct these interviews at our own expense and for the benefit of our readers.

Many of the companies we have interviewed have found great success subsequently. Our very first interview, with Organigram CEO Greg Engel in early 2018, was quite timely, just three months ahead of an inflection point in the company’s recovery from challenges in early 2017. We published an interview with Paul Benhaim, founder and then CEO of Elixinol Global in May 2018, spotlighting it on a very timely basis when the newly public company was relatively obscure.

Several companies were acquired shortly after we published interviews, including MPX Bioceutical, Hiku Brands, Medically Correct (incredibles), Quadron Cannatech, Origin House (pending), PharmaCann, Emblem, and ebbu, Finally, some of the investors we have profiled, like Merida Capital and Green Acre Capital, have been able to raise and deploy substantial capital. We continue to work hard to serve a professional readership which broadly spans from financial institutions, family offices, municipalities and regulatory authorities, as well as big law, accountancy, advisory, analysts, executives, academics, journalists, entrepreneurs and retail investors.

We are quite proud of the interviews we have shared to date, and we look forward to continuing to spotlight leading operators and investors in our dynamic industry.

As a top ten revenue generating cannabis company operating in the U.S., Cresco Labs is well positioned for the upcoming adult-use implementation in Illinois. Being operational in seven U.S. states, with binding transactions pending in California, New York, Massachusetts and Florida, as well as approved expansion into Michigan, Cresco is moving forward with a new retail cannabis experience with the national rollout of their Sunnyside* dispensaries.

To learn more about Cresco Labs, a client of New Cannabis Ventures, visit the company’s Investor Dashboard that we maintain on its behalf and click the blue Follow Company button in order to stay up to date with their progress.

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:

Exclusive article by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter